• Farid Ullah Khan Combined Military Hospital, Peshawar
  • Nauman Imtiaz Khan Combined Military Hospital, Peshawar
  • Muhammad Irfan Khan Combined Military Hospital, Peshawar
  • Ghazala Huma Khan Combined Military Hospital, Peshawar
  • Uzair Ahmad Khan Combined Military Hospital, Peshawar
  • Tahir Iqbal Mirza Combined Military Hospital, Peshawar




recurrance of varicose veins, booster dose, foam sclerotherapy


Background: Injection sclerotherapy administration is known to cause a decreased recurrence of varicose vein disease. This research aimed to investigate the recurrence of varicose vein disease after giving booster doses of injection sclerotherapy. The booster doses were given at 3rd and 6th months. Methods: 150 patients participated and all patients included ages were 30–70 in the category of ‘low risk’ patients. The patients were both males and females. Patients participating in the study were counselled appropriately and written consent was taken from them. Moreover, the patients selected were volunteers and agreed to be part of the study. Patients who were above 70 years of age, those who were at a high-risk due to some co-morbidities (high-risk patients), patients not willing for being part of the study, those allergic to drugs being used including sclerosant and people with any known psychiatric illness or cardiac arrhythmias, deep venous thrombosis patients, patients having arteriovenous malformation/venous ulcers were all excluded. If the patient was pregnant, the gynaecology team was taken on board and the procedure was carried out. Every procedure was carried out under the direct supervision of the supervisor. Booster dose sessions of Foam Sclerotherapy were held at 3rd and 6th months of the study time. Their effectiveness was clearly observed and documentation was carried out. Results: Since it was a procedure that could be done in the OPD, there was no need for specialized anaesthesia care. It is of significant notice that when a patient of varicose veins was given a booster intravenous sclerosant injection at 3rd and 6th month of treatment, chances of recurrence decreased to 50%.

Author Biography

Nauman Imtiaz Khan, Combined Military Hospital, Peshawar

vascular dept cmh peshawar


Leu H, Vogt M, Pfrunder H, Odermatt B. Phlebosclerosis: disorder or disease? Vasa 1991;20:230–236.

Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg 2009;49(2):498–501.

Hach W. Spezielle Diagnostik Der Primären Varikose. Untersuchungen des extrafaszialen Venensystems unter besonderer Berücksichtigung der aszendierenden Pressphlebographie. Demeter 1981.

Pichot O, Sessa C, Bosson JL. Duplex imaging analysis of the long saphenous vein reflux: basis for strategy of endovenous obliteration treatment. Int Angiol 2002;21(4):333–6.

Abu-Own A, Scurr JH, Smith PDC. Saphenous vein reflux without incompetence at the saphenofemoral junction. Br J Surg 1994;81(10):1452–54.

Fratila A. Surgical treatment of primary varicosis. In: Ratz J, Geronemus R, Goldman M, Maloney M, Padilla R, editors. Textbook of dermatologic surgery. Philadelphia: Lippincott-Raven: 1998; p.593–620.

Stücker M, Moritz R, Altmeyer P, Reich-Schupke S. New concept: different types of insufficiency of the saphenofemoral junction identified by duplex as a chance for a more differentiated therapy of the great saphenous vein. Phlebology 2013;28(5):268–74.

Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, Frullini A, Gillet JL, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014;29(6):338–54.

Connor DE, Cooley-Andrade O, Goh WX, Ma DDF, Parsi K. Detergent sclerosants are deactivated and consumed by circulating blood cells. Eur J Vasc Endovasc Surg 2015;49(4):426–31.

Drake LA, Dinehart SM, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, et al. Guidelines of care for sclerotherapy treatment of varicose and teleangiectatic leg veins. J Am Acad Dermatol 1996;34(3):523–8.

Rabe E, Pannier-Fischer F, Gerlach H, Breu FX, Guggenbichler S, Zabel M. Guidelines for sclerotherapy of varicose veins. (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg 2004;30(5):687–93.

Hamel-Desnos C, Ouvry P, Benigni JP, Boitelle G, Schadeck M, Desnos P, et al. Comparison of 1 % and 3 % polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. “the 3/1 study” Eur J Vasc Endovasc Surg 2007;34(6):723–9.

Chen CH, Chiu CS, Yang CH. Ultrasound-guided foam sclerotherapy for treating incompetent great saphenous veins—results of 5 years of analysis and morphologic evolvement study. Dermatol Surg 2012;38(6):851–7.

Additional Files